Key facts
- It has raised $49.6M; the latest was Later Stage VC ($13.9M) in Jun 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Shenzhen Yifeng Investment Management Enterprise, Hangzhou Capital, Dunhong Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Qiyu Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Qiyu Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qiyu Biotech
Developer of macromolecular biopharmaceutical drug designed to treat refractory cancers and autoimmune diseases. The company's platform include hybridoma antibody humanization platform, single domain antibody platform and antibody engineering, enabling patients to receive proper treatment and relief for their symptoms and diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Employees
- 16
- Ownership
- Privately Held (backing)
Qiyu Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qiyu Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qiyu Biotech in its N-PORT filings yet. We sweep new filings monthly.